Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Inv. presentation
Appointed CFO
Quarterly results
Director departure
Appointed director

Aceragen, Inc. (IDRA) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/16/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "EXECUTIVE SEPARATION AGREEMENT This Executive Separation Agreement , is entered into as of August 15, 2023 , by and between John Taylor and Aceragen, Inc., a Delaware corporation . BACKGROUND",
"GENERAL ASSIGNMENT FOR THE BENEFIT OF CREDITORS"
07/21/2023 8-K Quarterly results
07/11/2023 8-K Quarterly results
05/30/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and...
Docs: "Aceragen, Inc. Receives Nasdaq Notice Regarding Delayed Form 10-Q Filing"
05/04/2023 8-K Quarterly results
02/06/2023 8-K Quarterly results
02/03/2023 8-K Quarterly results
01/18/2023 8-K Investor presentation
Docs: "2023 ACERAGEN 0 0.5 1 1.5 2 2.5"
01/17/2023 8-K Quarterly results
01/13/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "IDERA PHARMACEUTICALS, INC. 2022 EQUITY INCENTIVE PLAN"
01/11/2023 8-K Other Events  Interactive Data
11/23/2022 8-K Quarterly results
11/17/2022 8-K Quarterly results
11/14/2022 8-K Quarterly results
09/30/2022 8-K Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity ...
Docs: "AGREEMENT AND PLAN OF MERGER",
"IDERA PHARMACEUTICALS, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES Z NON-VOTING CONVERTIBLE PREFERRED STOCK",
"IDERA PHARMACEUTICALS, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES X PREFERRED STOCK",
"EXECUTIVE TRANSITION AND SEPARATION AGREEMENT This Executive Transition and Separation Agreement , is entered into as of the date set forth on the signature page below , by and between Vincent Milano and Idera Pharmaceuticals, Inc., a Delaware corporation . BACKGROUND WHEREAS, you currently serve as President and Chief Executive Officer of the Company; WHEREAS, you and the Company are parties to that certain Severance and Change of Control Agreement and that certain Invention, Non-Disclosure and Non-Competition Agreement ; WHEREAS, the Company intends to enter into that certain Agreement and Plan of Merger by and among the Company; Bell Merger Sub I, Inc., a Delaware corporation and wholly-owned subsidiary of Idera; Bell Merger Sub II, LLC, a Delaware limited liability company and wholly-o...",
"1216 Riggins Mill Road",
"Dan Salain 837 N Barfield Drive Marco Island, FL 34145",
"Execution Version",
"Execution Version",
"EXECUTIVE TRANSITION AND SEPARATION AGREEMENT This Executive Transition and Separation Agreement , is entered into as of the date set forth on the signature page below , by and between Daniel Soland and Idera Pharmaceuticals, Inc., a Delaware corporation . BACKGROUND WHEREAS, you currently serve as Senior Vice President, Chief Operating Officer of the Company; WHEREAS, you and the Company are parties to that certain Severance and Change of Control Agreement and that certain Invention, Non-Disclosure and Non-Competition Agreement ; WHEREAS, the Company intends to enter into that certain Agreement and Plan of Merger by and among the Company; Bell Merger Sub I, Inc., a Delaware corporation and wholly-owned subsidiary of Idera; Bell Merger Sub II, LLC, a Delaware limited liability company and ..."
09/28/2022 8-K Quarterly results
08/09/2022 8-K Quarterly results
Docs: "Idera Pharmaceuticals Reports Second Quarter 2022 Financial Results"
06/24/2022 8-K Quarterly results
05/27/2022 8-K Quarterly results
05/17/2022 8-K Quarterly results
05/05/2022 8-K Quarterly results
03/31/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Idera Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update"
12/14/2021 8-K Quarterly results
12/01/2021 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events ...
11/08/2021 8-K Quarterly results
Docs: "Idera Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update"
08/09/2021 8-K Quarterly results
Docs: "Idera Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update"
06/10/2021 8-K Quarterly results
05/18/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "GENERAL RELEASE",
"Idera Pharmaceuticals Announces Corporate Updates"
04/29/2021 8-K Quarterly results
03/18/2021 8-K Quarterly results
03/01/2021 8-K Quarterly results
01/13/2021 8-K Quarterly results
01/11/2021 8-K Quarterly results
01/05/2021 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy